Integrating Recently Approved Therapies into Psoriatic Arthritis Treatment Plans

Despite the availability of a variety of treatment options, many patients with psoriatic arthritis (PsA) continue to experience suboptimaloutcomes. Recent research, however, has resulted in severalnewly approved and investigational agents that are likely to improve patient outcomes. This activity will examine recently approved and investigationaltherapies and their potentialintegration into treatment.
Program Developer/Facilitator: MCM Education.
Medium: Online Presentation
Commerical Support: Supported by educational grants from AbbVie, Inc.; Celgene Corporation; and Janssen Biotech, Inc.,administered by Janssen Scientific Affairs, LLC.


Target Audience

Rheumatologists, dermatologists, and other clinicians who treat patients with PsA.


Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  • Summarize recent data on emerging investigational therapies for PsA;
  • Describe the optimal, evidence-based role of the PDE4 inhibitor apremilast in the treatment of PsA;
  • Describe the optimal, evidence-based role of the IL-12/23 antagonist ustekinumab in the treatment of PsA.


Additional information
ACGME/ABMS Core Competencies: 
Medical Knowledge
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Activity opens: 
Activity expires: 
  James J. Curran, MD
  Professor of Medicine
  Department of Rheumatology
  The University of Chicago School of Medicine
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Chicago Pritzker School of Medicine and MCM Education. The University of Chicago Pritzker School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses and other healthcare professionals will receive a Certificate of Participation. For information on the applicability and acceptance of certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME, please consult your professional licensing board.
Registration: To view this activity, you will need to visit the ProCME website.
Click here to view the activity or if you are logged in click on the "Complete Activity" button!
Please login or create an account to proceed.